ITGR · Integer Holdings Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $439.58M | - | $467.69M | $476.49M | $437.39M | - | $431.42M | $436.20M | $414.81M | - |
| Cost of Revenue | $329.99M | - | $341.53M | $347.34M | $317.07M | - | $314.85M | $316.81M | $304.96M | - |
| Gross Profit | $109.59M | - | $126.16M | $129.15M | $120.32M | - | $116.57M | $119.39M | $109.84M | - |
| R&D | $16.24M | - | $10.95M | $14.24M | $14.20M | - | $11.92M | $16.10M | $15.75M | - |
| SG&A | $58.71M | - | $50.45M | $52.92M | $51.16M | - | $44.82M | $47.12M | $46.93M | - |
| Total Operating Expenses | $77.73M | - | $69.72M | $69.81M | $70.77M | - | $58.56M | $64.21M | $70.56M | - |
| D&A | $35.01M | - | - | - | $29.83M | - | - | - | $26.18M | - |
| Operating Income | $31.87M | - | $56.44M | $59.34M | $49.55M | - | $58.01M | $55.19M | $39.28M | - |
| Interest Expense | $9.73M | - | $9.37M | $9.75M | $13.99M | - | $11.49M | $11.46M | $14.67M | - |
| Income Tax | $3.85M | - | $6.31M | $8.59M | $9.47M | - | $7.14M | $8.78M | $4.23M | - |
| Net Income | $16.51M | - | $39.68M | $37.01M | ($22.49M) | - | $35.44M | $31.25M | $20.51M | - |
| EPS - Basic | $0.48 | - | $1.13 | $1.06 | ($0.66) | - | $1.05 | $0.93 | $0.61 | - |
| EPS - Diluted | $0.48 | - | $1.11 | $1.04 | ($0.66) | - | $0.99 | $0.88 | $0.59 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.12M | $17.16M | $58.94M | $23.14M | $31.71M | $46.54M | $35.57M | $34.14M | $42.16M | $23.67M |
| Accounts Receivable | $327.78M | $346.08M | $310.17M | $302.26M | $276.24M | $245.27M | $241.71M | $240.50M | $237.15M | $238.28M |
| Inventory | $284.48M | $253.74M | $263.54M | $266.44M | $260.10M | $247.13M | $265.42M | $272.33M | $262.87M | $239.72M |
| Accounts Payable | $115.00M | $113.13M | $110.74M | $117.37M | $112.02M | $101.50M | $116.84M | $119.45M | $116.22M | $120.29M |
| Current Assets | $774.76M | $770.10M | $778.12M | $737.43M | $702.20M | $671.12M | $730.03M | $676.98M | $668.57M | $617.67M |
| Total Assets | $3.41B | $3.41B | $3.40B | $3.37B | $3.30B | $3.08B | $3.17B | $3.13B | $3.12B | $2.94B |
| Current Liabilities | $206.34M | $232.04M | $209.82M | $216.03M | $206.40M | $227.17M | $222.40M | $205.99M | $201.43M | $220.97M |
| Long-term Debt | $1.25B | $1.19B | $1.19B | $1.20B | $1.24B | $980.15M | $1.07B | $1.12B | $1.14B | $959.92M |
| Total Liabilities | $1.71B | $1.66B | $1.65B | $1.67B | $1.69B | $1.46B | $1.55B | $1.57B | $1.59B | $1.42B |
| Stockholders' Equity | $1.70B | $1.75B | $1.75B | $1.70B | $1.61B | $1.62B | $1.62B | $1.55B | $1.53B | $1.52B |
| Retained Earnings | $1.01B | $994.05M | $945.45M | $905.77M | $868.76M | $891.25M | $858.54M | $823.11M | $791.86M | $771.35M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $24.70M | - | - | - | $31.28M | - | - | - | $23.24M | - |
| Investing Cash Flow | ($37.90M) | - | - | - | ($197.17M) | - | - | - | ($168.20M) | - |
| Financing Cash Flow | $3.83M | - | - | - | $151.58M | - | - | - | $163.29M | - |
| CapEx | $23.96M | - | - | - | $25.22M | - | - | - | $29.07M | - |
| Free Cash Flow | $737.0K | - | - | - | $6.06M | - | - | - | ($5.83M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 24.9% | - | 27.0% | 27.1% | 27.5% | - | 27.0% | 27.4% | 26.5% | - |
| Operating margin | 7.2% | - | 12.1% | 12.5% | 11.3% | - | 13.4% | 12.7% | 9.5% | - |
| EBITDA margin | 15.2% | - | - | - | 18.1% | - | - | - | 15.8% | - |
| Net margin | 3.8% | - | 8.5% | 7.8% | -5.1% | - | 8.2% | 7.2% | 4.9% | - |
| Free cash flow margin | 0.2% | - | - | - | 1.4% | - | - | - | -1.4% | - |
| FCF / Net income | 0.04 | - | - | - | -0.27 | - | - | - | -0.28 | - |
| R&D / Revenue | 3.7% | - | 2.3% | 3.0% | 3.2% | - | 2.8% | 3.7% | 3.8% | - |
| SG&A / Revenue | 13.4% | - | 10.8% | 11.1% | 11.7% | - | 10.4% | 10.8% | 11.3% | - |
| Effective tax rate | 18.9% | - | 13.7% | 18.8% | - | - | 16.8% | 21.9% | 17.1% | - |
| Return on assets | 0.5% | - | 1.2% | 1.1% | -0.7% | - | 1.1% | 1.0% | 0.7% | - |
| Return on equity | 1.0% | - | 2.3% | 2.2% | -1.4% | - | 2.2% | 2.0% | 1.3% | - |
| Return on invested capital | 0.9% | - | 1.7% | 1.7% | 1.4% | - | 1.8% | 1.6% | 1.2% | - |
| Liquidity | ||||||||||
| Current ratio | 3.75 | 3.32 | 3.71 | 3.41 | 3.40 | 2.95 | 3.28 | 3.29 | 3.32 | 2.80 |
| Quick ratio | 2.38 | 2.23 | 2.45 | 2.18 | 2.14 | 1.87 | 2.09 | 1.96 | 2.01 | 1.71 |
| Cash ratio | 0.04 | 0.07 | 0.28 | 0.11 | 0.15 | 0.20 | 0.16 | 0.17 | 0.21 | 0.11 |
| Leverage | ||||||||||
| Debt / Equity | 0.74 | 0.68 | 0.68 | 0.71 | 0.77 | 0.61 | 0.66 | 0.72 | 0.75 | 0.63 |
| Debt / Assets | 0.37 | 0.35 | 0.35 | 0.36 | 0.37 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 |
| Debt / EBITDA | 18.71 | - | - | - | 15.56 | - | - | - | 17.43 | - |
| Interest coverage | 3.3x | - | 6.0x | 6.1x | 3.5x | - | 5.0x | 4.8x | 2.7x | - |
| Equity multiplier | 2.01 | 1.95 | 1.95 | 1.98 | 2.05 | 1.90 | 1.95 | 2.01 | 2.04 | 1.94 |
| Liabilities / Assets | 0.50 | 0.49 | 0.49 | 0.49 | 0.51 | 0.47 | 0.49 | 0.50 | 0.51 | 0.48 |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | - | 0.14 | 0.14 | 0.13 | - | 0.14 | 0.14 | 0.13 | - |
| Inventory turnover | 1.16 | - | 1.30 | 1.30 | 1.22 | - | 1.19 | 1.16 | 1.16 | - |
| Days sales outstanding | 272d | - | 242d | 232d | 231d | - | 204d | 201d | 209d | - |
| Days inventory outstanding | 315d | - | 282d | 280d | 299d | - | 308d | 314d | 315d | - |
| Days payable outstanding | 127d | - | 118d | 123d | 129d | - | 135d | 138d | 139d | - |
| Cash conversion cycle | 460d | - | 405d | 388d | 401d | - | 377d | 377d | 384d | - |
| Valuation | ||||||||||
| P / E | 180.9x | - | 91.4x | 117.8x | - | - | 127.2x | 131.6x | 197.8x | - |
| P / B | 1.8x | - | 2.1x | 2.6x | 2.5x | - | 2.8x | 2.6x | 2.7x | - |
| P / S | 6.8x | - | 7.7x | 9.2x | 9.1x | - | 10.4x | 9.4x | 9.8x | - |
| EV / EBITDA | 63.3x | - | - | - | 65.1x | - | - | - | 79.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.5% | - | 8.4% | 9.2% | 5.4% | - | 6.6% | 9.0% | 9.5% | - |
| Revenue CAGR (3y) | 5.1% | - | 10.9% | 10.8% | 12.0% | - | 12.2% | 22.0% | 12.6% | - |
| Revenue CAGR (5y) | 8.6% | - | 14.7% | 14.7% | 5.9% | - | 7.3% | 6.8% | 5.7% | - |
| Gross profit growth (YoY) | -8.9% | - | 8.2% | 8.2% | 9.5% | - | 10.4% | 12.8% | 13.6% | - |
| Operating income growth (YoY) | -35.7% | - | -2.7% | 7.5% | 26.2% | - | 20.7% | 32.7% | 15.0% | - |
| Net income growth (YoY) | - | - | 12.0% | 18.4% | - | - | 30.0% | 30.3% | 57.0% | - |
| EPS growth (YoY) | - | - | 12.1% | 18.2% | - | - | 22.2% | 23.9% | 51.3% | - |
| EPS CAGR (3y) | 7.2% | - | 32.2% | 18.8% | - | - | 14.5% | -0.4% | -3.2% | - |
| EPS CAGR (5y) | -5.9% | - | 3.8% | 153.2% | - | - | 1.5% | -2.5% | -2.2% | - |
| FCF growth (YoY) | -87.8% | - | - | - | - | - | - | - | 68.5% | - |
| FCF CAGR (5y) | -51.9% | - | - | - | -19.1% | - | - | - | - | - |
| Book value growth (YoY) | 5.6% | 7.9% | 7.7% | 9.6% | 5.4% | 6.6% | 10.8% | 7.5% | 7.6% | 7.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.85B totalReportable Segment$1.85B · 100.0%
Product / service
$1.85B totalCardio And Vascular$1.11B · 59.7%
Cardiac Rhythm Management Neuromodulation$668.80M · 36.1%
Other Markets$77.75M · 4.2%
Geographic
$1.85B totalUS$979.81M · 52.9%
Rest Of World$469.88M · 25.3%
CR$173.52M · 9.4%
PR$131.26M · 7.1%
IE$99.16M · 5.3%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Integer Holdings Corp against the 5 most active filers in the same SIC group.